## AFI Scoping Review Full Text Data Collection Form Version 1.0

| udy ID (as assigned)                                   | Name of Reviewer          | initials)                     |                                      |  |
|--|---------------------------|-------------------------------|--------------------------------------|--|
|  |                           |                               |                                      |  |
| ar of Study Publication (YYYY)                         |                           |                               |                                      |  |
| ar Study Started (YYYY)                                | Month of Study Start      | (If Applicable)               |                                      |  |
| :  |                           |                               |                                      |  |
| ar Study Ended (YYYY)                                  | Month of Study End        | (If Applicable)               |                                      |  |
| t B: Study Setting, F                                  | unding, and R             | esearchers                    |                                      |  |
| umber of Countries Study Conduct                       |                           |                               |                                      |  |
|  |                           |                               |                                      |  |
| Country Name   |                           |                               |                                      |  |
| Name of country 1                                      | Name of country 2         | <u></u>                       | Name of country 3                    |  |
| Name of country 4                                      | Name of country 5         |                               | Name of country 6                    |  |
| •  |                           | <b>-</b> ]∷∷                  | ▼]∷∷                                 |  |
| Study Population Setting (per —<br>mention in article) | Setting of Patient I      | Encounter                     |                                      |  |
| •  | Inpatient Only            |                               |                                      |  |
| <ul><li>○ Urban</li><li>○ Rural</li></ul>              | Ambulatory/Emergency Only |                               |                                      |  |
| Both   | Community Only            |                               |                                      |  |
| Not specified  | Mixed     Not Defined     |                               |                                      |  |
| Type of funding organization (Che                      | ck all that apply)        | Type of author                | affiliation (Check all that apply)   |  |
| Academia:  |                           | Academia                      |                                      |  |
| Foreign Government                                     |                           |                               | Foreign Government  Local Government |  |
| Local Government                                       |                           |                               |                                      |  |
|  |                           |                               | n, NGO, Charity                      |  |
| Foundation, NGO, Charity                               |                           | <ul> <li>Corporate</li> </ul> | , Pharma, Biotech                    |  |
| . <del></del>  |                           | . Corporate                   |                                      |  |
| Foundation, NGO, Charity                               | who)                      |                               | al organization (e.g. WHO)           |  |
| Foundation, NGO, Charity  Corporate, Pharma, Biotech   |                           | Multilatera                   |                                      |  |

#### Part C: Design Study Design Control Group How control was selected? (briefly explain) Case Series Yes Cross-Sectional No Population Under Surveillance Known Cohort Not Applicable (specifically mentioned or can be Case-Controlled inferred) Interventional Study Design Temporality Yes Surveillance No Cross-Sectional Other Not applicable Prospective Not mentioned and can't be inferred Retrospective Study Design Other (briefly explain) Unspecified Study Age Range (Check all that apply if study age range Was any type of seasonality reported? (figure or table or even partically included) mentioned in text) Neonate (<1m)</p> Toung Adult (20-39y) Yes No Infant (1m-23m) Middle-Aged Adult (40-59y) How seasonality reported (briefly explain including pathogens) Children (2-9y) Elderly (>=60y) Adolescents (10-19y) Primary Study Objective (Check the most appropriate one) Other Primary Study Objective Epi assessment of etiology – species level (e.g. Plasmodium falciparum) Epi assessment of etiology – genus level (e.g. Rickettsia spp.) To broadly define AFI etiology (e.g. multiple species/genus) Describe Clinical Scenario Study Diagnostic Test Assess Intervention Detection of Novel or Emerging Pathogen Other or Uncertain (Please explain in detail) Secondary Study Objectives (Check all that Other Secondary Study Objective apply, both mentioned or inferred) Epi assessment of etiology - species level Epi assessment of etiology - genus level To broadly define AFI etiology Describe Clinical Scenario

Study Diagnostic Test

Other or Uncertain (Please explain in detail)

Assess Intervention

#### Part D: AFI Definition AFI terminology Terminology to describe acute fever in the study If other, please specify **Measured Fever** Axillary Fever Cutoff Temporal Fever Cutoff Tympanic Fever Cutoff Rectal Fever Cutoff Unspecified Location Cutoff Oral Fever Cutoff Subjective Fever Use of Tactile Fever Subjective Fever Number of days specified If specified, write number of days Yes Specified Not specified No Not specified **Exclusion Criteria** Medical History Other (Specify) Upper Limit of Fever Duration Previously Diagnosed Cause Recent Antibiotic Use Symptoms Upper/Lower Respiratory Symptoms Skin/Soft Tissue Infection STI Symptoms Gastrointestinal Symptoms CNS Symptoms Other (Specify) Urinary Tract Symptoms Dengue Hemorrhagic Fever Symptoms Past Medical History ■ HIV Renal Failure Recent/Planned Surgery Other (Specify) Hepatic Failure Malignancy Trauma Lab Tests Malaria Positive Other Pathogen Test (Specify) Lab Value (Specify) Other Exclusion Criteria Describe "other" **Inclusion Criteria** Past Medical History Fever Longer Than Specific Interval HIV Renal Failure Other (Specify) Lab Tests Lab Value (Specify) Malaria Positive MalariaNegative Other Pathogen Test (Specify) Other Specific Inclusion Free Text Inclusion

# Part E: Overall Study Results and Diagnostics

| dy Overall Results                      |                               |  |
|---|-------------------------------|--|
| Number of AFI cases enroll              | ed                            | Number of controls enrolled (if applicable)                  |
|   |                               |  |
| Number Pathogens Tested                 | except by culture (for AFI)   | Number Pathogens Tested except by culture (As control to AF  |
| Total number of AFI cases               | diagnosed (per article)       | Total number of controls diagnosed (per article)             |
| Percentage AFI Cases Defi               | ined (diagnosed)              | Percentage Controls Defined (If Applicable)                  |
| Was co-infection reported?              |                               |  |
|   | <u> </u>                      |  |
| ti-pathogen Laboratory Plat             | form                          |  |
| Blood Culture Algorithm                 | Blood Culture System          |  |
|   | Culture Speciation            |  |
|   | Other information regar       | rding blood culture  |
| Respiratory Viral Panel                 | Panel Name                    |  |
| , | Respiratory Panel Spec        | imen type  |
|   |                               |  |
| Stool Enteric Panel                     | Enteric Panel Name            |  |
| Blood PCR                               | Blood PCR Name                |  |
|   | PCR Specimen Type             |  |
| ther platform                           |                               |  |
|   |                               |  |
|   |                               |  |
| Number of Pathogens Ider                | ntified in the Study? (Consid | fer sub-species as one except Samonella typhi and non-typhoi |
| Number of Pathogens Ider                | ntified in the Study? (Consid | der sub-species as one except Samonella typhi and non-typhoi |

### Instructions

- Please complete this for every pathogen.
- If there is only one diagnostic modality used for a pathogen, please just fill out for one.
- Check "confirmatory test" only when the study used confirmatory diagnostics for the pathogen
- Please use Comments section for any other information. (Assay, etc.)
- Use only numeric values for total specimens tested and total specimens tested positive. (Not proportions)

| Name of Pathogen            | Other Pathogen Specify                    |  |
|-----------------------------|---|--|
|                             | •   |  |
| Test Modality 1             | Sample Type 1 ▼                           | Test Modality 1 Product Name (If Applicable) |
| Total Specimens Tested 1    | Total Specimens Tested Positive           | 1 Confirmatory Test                          |
| Test Modality 2             | Sample Type 2                             | Test Modality 2 Product Name (If Applicable) |
| Total Specimens Tested 2    | Total Specimens Tested Positive           | 2 Confirmatory Test                          |
| Test Modality 3             | Sample Type 3 ▼                           | Test Modality 3 Product Name (If Applicable) |
| Total Specimens Tested 3    | Total Specimens Tested Positive           | 3 Confirmatory Test                          |
| Convalescent samples tester | d (If Applicable)  ▼                      |  |
|                             | nything significant that were left out fo |  |